Scott Alexander O'Brien is VP at GenMark Diagnostics, Inc. (GNMK). They have made 15 open-market trades across 1 company since 2020, most recently 2021-04-22.
CIK 0001805551
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 15 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| GNMK | 170,879 | $4.1M |
Shares reported on the most recent Form 4, priced at the 2021-03-08 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| GNMK | SELL | 2021-01-27 | 2021-01-29 | $14.06 | $3K | +22.1% | +37.9% | N/A |
| GNMK | SELL | 2021-01-25 | 2021-01-25 | $14.23 | $184K | -6.4% | +24.0% | N/A |
| GNMK | SELL | 2020-12-07 | 2020-12-09 | $13.97 | $10K | +16.1% | +30.0% | +55.7% |
| GNMK | SELL | 2020-11-24 | 2020-11-25 | $13.17 | $15K | +8.8% | +20.2% | +55.1% |
| GNMK | SELL | 2020-11-03 | 2020-11-04 | $12.73 | $3K | -1.6% | +2.0% | +0.1% |
| GNMK | SELL | 2020-10-27 | 2020-10-29 | $11.34 | $2K | -0.4% | +7.9% | +8.3% |
| GNMK | SELL | 2020-09-08 | 2020-09-10 | $11.02 | $8K | +16.6% | +1.6% | +6.9% |
| GNMK | SELL | 2020-08-25 | 2020-08-26 | $14.14 | $17K | -14.2% | +1.7% | -3.2% |
| GNMK | SELL | 2020-08-17 | 2020-08-18 | $15.38 | $1.1M | -17.5% | -23.3% | -14.6% |
| GNMK | SELL | 2020-08-04 | 2020-08-05 | $18.93 | $4K | -17.0% | -39.8% | -30.9% |
| GNMK | SELL | 2020-07-28 | 2020-07-29 | $17.30 | $3K | -8.1% | -22.3% | -30.3% |
| GNMK | SELL | 2020-06-08 | 2020-06-09 | $9.14 | $7K | +43.8% | +105.4% | +23.6% |
| GNMK | SELL | 2020-05-28 | 2020-06-01 | $9.52 | $11K | -0.8% | +51.5% | +31.7% |
| GNMK | SELL | 2020-05-05 | 2020-05-06 | $13.49 | $3K | -4.0% | -17.2% | +73.0% |
| GNMK | SELL | 2020-04-29 | 2020-05-01 | $11.64 | $2K | -0.3% | -15.7% | +51.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.